🔎 Trials Near Me

Home › Metastatic Cancer › Nebraska › Omaha

Metastatic Cancer clinical trials in Omaha, NE

14 studies for Metastatic Cancer are looking for participants at sites in and around Omaha (within about 30 miles). Open a study to see who can join and how to contact the study team.

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

RecruitingPhase 1
  • Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07277413

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

RecruitingPhase 2/3
  • Nebraska Medicine, Omaha
  • Nebraska Medicine - Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06989437

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

RecruitingPhase 2
  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07007559

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

RecruitingPhase 1/2
  • University of Nebraska Medical Center Buffet Cancer Center, Omaha
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

RecruitingPhase 2/3
  • University of Nebraska Medical Center, Omaha
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06943755

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

RecruitingPhase 3
  • Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

RecruitingPhase 3
  • Research Site, Omaha
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07205822

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

RecruitingPhase 2
  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06769698

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

RecruitingPhase 3
  • Nebraska Methodist Hospital, Omaha
Ages 18 and older · All sexes · Updated Jun 16, 2026 · NCT05208047

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

RecruitingPhase 1
  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05283330

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

RecruitingPhase 1/2
  • Nebraska Cancer Specialists, Omaha
Ages 18 and older · All sexes · Updated Feb 18, 2026 · NCT07030257

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

RecruitingPhase 3
  • Nebraska Methodist Hospital, Omaha
Ages 18 and older · All sexes · Updated Feb 6, 2026 · NCT06127407

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

RecruitingObservational study
  • Massive Bio SYNERGY-AI site, Omaha
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

RecruitingPhase 1
  • Nebraska Cancer Specialists (NCS), Omaha
Ages 18 and older · All sexes · Updated Nov 7, 2024 · NCT06190886

Metastatic Cancer trials in other cities

Other studies in Omaha

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.